LCI VS ALRN Stock Comparison
Performance
LCI10/100
10/100
LCI returned -74.42% in the last 12 months. Based on the other stocks in its sector with an average return of -23.90%, its performance is below average giving it a grade of 10 of 100.
ALRN10/100
10/100
ALRN returned -54.46% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Forecast
LCI64/100
64/100
7 analysts offer 12-month price forecasts for LCI. Together, they have an average target of 0, the most optimistic forecast put LCI at 0 within 12-months and the most pessimistic has LCI at 0.
ALRN
"Forecast" not found for ALRN
Technicals
LCI21/100
21/100
LCI receives a 21 of 100 based on 14 indicators. 3 are bullish, 11 are bearish.
ALRN50/100
50/100
ALRN receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.
Earnings
LCI10/100
10/100
LCI has missed earnings 9 times in the last 20 quarters.
ALRN10/100
10/100
ALRN has missed earnings 9 times in the last 20 quarters.
Profit
LCI10/100
10/100
Out of the last 4 quarters, LCI has had 0 profitable quarters and has increased their profits year over year on 0 of them.
ALRN10/100
10/100
Out of the last 20 quarters, ALRN has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
LCI48/100
48/100
LCI has had a lower than average amount of volatility over the last 12 months giving it a grade of 47 of 100.
ALRN59/100
59/100
ALRN has had a higher than average amount of volatility over the last 12 months giving it a score of 59 of 100.
Analyst Price Targets
LCI
"Analyst Price Targets" not found for LCI
ALRN100/100
100/100
4 analysts offer 12-month price targets for ALRN. Together, they have an average target of 0, the most optimistic target put ALRN at 0 within 12-months and the most pessimistic has ALRN at 0.
All score calculations are broken down here to help you make more informed investing decisions
Lannett Company, Inc. Summary
New York Stock Exchange / LCI
Healthcare
Drug Manufacturers—Specialty & Generic
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.
Aileron Therapeutics, Inc. Common Stock Summary
Nasdaq / ALRN
Healthcare
Biotechnology
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare LCI to other companies in the same or a similar industry.